The7.16.4monoclonalantibodyreactswithhumanandratHER2(humanepidermalgrowthfactorreceptor2)alsoknownasneupeptide,CD340,ErbB-2,andp185.HER2isa185kDatransmembrane,receptor-likeglycoproteinwithintrinsictyrosinekinaseactivitythatispartofseveralcellsurfacereceptorcomplexes.HER2lacksanidentifiedligandhowever,thekinasecanbeactivatedintheabsenceofaligandwhenoverexpressed.HER2isaproto-oncoproteinthatiscommonlyoverexpressedonavarietyofdifferenttumors.Approximately40%ofhumanbreastcancersoverexpressHER2.HER2overexpressionisassociatedwithpooreroverallsurvivalrates,shortertimestodiseaseprogression,andincreasedresistancetochemotherapy.Becauseoftheseclinicalcharacteristicsanti-HER2monoclonalantibodytherapyisnowastandardforthetreatmentofadvancedbreastcancersthatoverexpressHER2.The7.16.4antibodyhasbeenshowntoinhibitthegrowthofHER2-overexpressingtumorsbothinvitroandinvivo.
| Isotype | MouseIgG2a |
| RecomendedIsotypeControl(s) | InVivoMAbmouseIgG2aisotypecontrol,unknownspecificity |
| RecommendedInVivoPureDilutionBuffer | InVivoPurepH7.0DilutionBuffer |
| Immunogen | neu-transfectedNIH3T3cells |
| ReportedApplications |
|
| Endotoxin |
|
| Purity |
|
| Formulation |
|
| Sterility | 0.2μMfiltered |
| Production | Purifiedfromtissueculturesupernatantinananimalfreefacility |
| Purification | ProteinG |
| Storage | Undilutedat4°Cinthedark |
